The landscape of pharmaceutical research is constantly evolving, with a persistent focus on developing effective treatments for prevalent diseases such as diabetes. Central to this advancement is the availability and understanding of key chemical intermediates. One such compound gaining significant attention is (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide, identified by its CAS number 521284-19-5.

This molecule, characterized by its 'Off-White to Pale Yellow Solid' appearance, plays a crucial role as a pharmaceutical intermediate. Its significance is particularly pronounced in the synthesis of (aminothiazolyl)acetanilide derivatives, a class of compounds explored for their potential in managing diabetes. As a manufacturer and supplier in China, understanding the precise chemical properties and applications of such intermediates is paramount.

The compound's molecular formula is C16H16N2O4, with a molecular weight of approximately 300.31 g/mol. Its solubility in DMSO and Methanol, albeit slight, is an important factor for chemists when planning synthesis reactions. The detailed understanding of its properties allows for more efficient and predictable chemical synthesis, which is vital when aiming to buy high-quality materials for research and development.

The synthesis of (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide often involves meticulous chemical processes to ensure high purity. As a pharmaceutical intermediate, its quality directly impacts the efficacy and safety of the final drug product. Therefore, sourcing this compound from reputable suppliers who prioritize quality assurance is essential for any organization involved in pharmaceutical innovation.

Furthermore, this compound is recognized as a Mirabegron intermediate. Mirabegron itself is a well-known medication. The linkage between this intermediate and such established drugs underscores its importance in the pharmaceutical supply chain. For researchers looking to explore new avenues in diabetes treatment or other therapeutic areas, securing a reliable supply of such intermediates is a foundational step. The price and availability from established manufacturers in China continue to be key factors for global accessibility.

In conclusion, (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide represents more than just a chemical compound; it is a vital link in the chain of pharmaceutical discovery and production. Its application in diabetes treatment development and its role as a key intermediate highlight the continuous innovation within the fine chemical sector. For researchers and pharmaceutical companies, understanding and securing access to these essential building blocks is critical for future breakthroughs.